149 related articles for article (PubMed ID: 21441959)
41. Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation.
Gruhn B; Meerbach A; Häfer R; Zell R; Wutzler P; Zintl F
Bone Marrow Transplant; 2003 Jun; 31(11):1023-5. PubMed ID: 12774054
[TBL] [Abstract][Full Text] [Related]
42. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
Greenfield HM; Gharib MI; Turner AJ; Guiver M; Carr T; Will AM; Wynn RF
Pediatr Blood Cancer; 2006 Aug; 47(2):200-5. PubMed ID: 16206207
[TBL] [Abstract][Full Text] [Related]
43. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients.
Barker JN; Martin PL; Coad JE; DeFor T; Trigg ME; Kurtzberg J; Weisdorf DJ; Wagner J
Biol Blood Marrow Transplant; 2001; 7(7):395-9. PubMed ID: 11529490
[TBL] [Abstract][Full Text] [Related]
44. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation.
Brunstein CG; Weisdorf DJ; DeFor T; Barker JN; Tolar J; van Burik JA; Wagner JE
Blood; 2006 Oct; 108(8):2874-80. PubMed ID: 16804113
[TBL] [Abstract][Full Text] [Related]
45. Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning.
Li Q; Rane L; Poiret T; Zou J; Magalhaes I; Ahmed R; Du Z; Vudattu N; Meng Q; Gustafsson-Jernberg Å; Winiarski J; Ringdén O; Maeurer M; Remberger M; Ernberg I
Oncotarget; 2016 May; 7(21):30230-40. PubMed ID: 27102298
[TBL] [Abstract][Full Text] [Related]
46. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease.
Okamura T; Kishimoto T; Inoue M; Honda M; Yamashita N; Wakiguchi H; Yagita M; Hosoi G; Sako M; Yasui M; Yagi K; Kawa K
Bone Marrow Transplant; 2003 Jan; 31(2):105-11. PubMed ID: 12621491
[TBL] [Abstract][Full Text] [Related]
47. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for adult T cell leukemia.
Ogata M; Satou T; Kawano R; Yoshikawa T; Ikewaki J; Kohno K; Ando T; Miyazaki Y; Ohtsuka E; Saburi Y; Kikuchi H; Saikawa T; Kadota J
J Med Virol; 2011 Apr; 83(4):702-9. PubMed ID: 21328386
[TBL] [Abstract][Full Text] [Related]
48. Post-transplant EBV-related lymphoproliferative disorder complicating umbilical cord blood transplantation in patients of adrenoleukodystrophy.
Cheng FW; Lee V; To KF; Chan KC; Shing MK; Li CK
Pediatr Blood Cancer; 2009 Dec; 53(7):1329-31. PubMed ID: 19591223
[TBL] [Abstract][Full Text] [Related]
49. Use of nonvolume-reduced (unmanipulated after thawing) umbilical cord blood stem cells for allogeneic transplantation results in safe engraftment.
Hahn T; Bunworasate U; George MC; Bir AS; Chinratanalab W; Alam AR; Bambach B; Baer MR; Slack JL; Wetzler M; Becker JL; McCarthy PL
Bone Marrow Transplant; 2003 Jul; 32(2):145-50. PubMed ID: 12838278
[TBL] [Abstract][Full Text] [Related]
50. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation.
Cesaro S; Murrone A; Mengoli C; Pillon M; Biasolo MA; Calore E; Tridello G; Varotto S; Alaggio R; Zanesco L; Palù G; Messina C
Br J Haematol; 2005 Jan; 128(2):224-33. PubMed ID: 15638858
[TBL] [Abstract][Full Text] [Related]
51. A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation.
Cesaro S; Pegoraro A; Tridello G; Calore E; Pillon M; Varotto S; Abate D; Barzon L; Mengoli C; Carli M; Messina C
Transplantation; 2010 Jun; 89(12):1533-40. PubMed ID: 20463647
[TBL] [Abstract][Full Text] [Related]
52. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT.
Ocheni S; Kroeger N; Zabelina T; Sobottka I; Ayuk F; Wolschke C; Muth A; Lellek H; Petersen L; Erttmann R; Kabisch H; Zander AR; Bacher U
Bone Marrow Transplant; 2008 Aug; 42(3):181-6. PubMed ID: 18516079
[TBL] [Abstract][Full Text] [Related]
53. Reduced-intensity conditioning regimens before unrelated cord blood transplantation in adults with acute leukaemia and other haematological malignancies.
Rocha V; Mohty M; Gluckman E; Rio B; ; ;
Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S31-4. PubMed ID: 19561411
[TBL] [Abstract][Full Text] [Related]
54. Reactivation of Epstein-Barr virus in B cells of patients with chronic hepatitis C.
Shimozuma Y; Ito T; Inokuchi M; Uchikoshi M; Miyashita M; Nozawa H; Shimazaki T; Hiroishi K; Imawari M
J Med Virol; 2010 Dec; 82(12):2064-72. PubMed ID: 20981794
[TBL] [Abstract][Full Text] [Related]
55. Pre-engraftment syndrome after unrelated donor umbilical cord blood transplantation in patients with hematologic malignancies.
Wang X; Liu H; Li L; Geng L; Ding K; Liu X; Tong J; Zhu W; Sun Z
Eur J Haematol; 2012 Jan; 88(1):39-45. PubMed ID: 21933279
[TBL] [Abstract][Full Text] [Related]
56. Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia.
Sanz J; Montesinos P; Saavedra S; Lorenzo I; Senent L; Planelles D; Larrea L; Martín G; Palau J; Jarque I; Martínez J; de la Rubia J; Moscardó F; Martinez D; Gómez I; López M; Sanz MA; Sanz GF
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1589-95. PubMed ID: 20553927
[TBL] [Abstract][Full Text] [Related]
57. High level of perforin expression in T cells: An early prognostic marker of the severity of herpesvirus reactivation after allogeneic stem cell transplantation in adults.
Pietersma FL; van Dorp S; Jacobi R; Ran L; Nanlohy NM; Schuurman R; Minnema MC; Meijer E; van Baarle D
Clin Infect Dis; 2010 Mar; 50(5):717-25. PubMed ID: 20121571
[TBL] [Abstract][Full Text] [Related]
58. Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation.
Delapierre B; Reman O; Dina J; Breuil C; Bellal M; Johnson-Ansah H; Gac AC; Damaj G; Chantepie S
Curr Res Transl Med; 2019 Nov; 67(4):145-148. PubMed ID: 30871955
[TBL] [Abstract][Full Text] [Related]
59. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection.
Kawa K; Sawada A; Sato M; Okamura T; Sakata N; Kondo O; Kimoto T; Yamada K; Tokimasa S; Yasui M; Inoue M
Bone Marrow Transplant; 2011 Jan; 46(1):77-83. PubMed ID: 20498651
[TBL] [Abstract][Full Text] [Related]
60. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation.
Rodrigues CA; Sanz G; Brunstein CG; Sanz J; Wagner JE; Renaud M; de Lima M; Cairo MS; Fürst S; Rio B; Dalley C; Carreras E; Harousseau JL; Mohty M; Taveira D; Dreger P; Sureda A; Gluckman E; Rocha V
J Clin Oncol; 2009 Jan; 27(2):256-63. PubMed ID: 19064984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
